GlaxoSmithKline’s (GSK) Buy Rating Reiterated at Societe Generale

Societe Generale restated their buy rating on shares of GlaxoSmithKline (NYSE:GSK) in a research note issued to investors on Friday morning, The Fly reports.

A number of other research firms also recently commented on GSK. AlphaValue raised shares of GlaxoSmithKline to a buy rating in a report on Tuesday, September 1st. Zacks Investment Research downgraded shares of GlaxoSmithKline from a buy rating to a hold rating and set a $41.00 price objective for the company. in a report on Tuesday, September 15th. UBS Group reaffirmed a buy rating on shares of GlaxoSmithKline in a report on Wednesday, August 12th. Morgan Stanley reaffirmed an underweight rating on shares of GlaxoSmithKline in a report on Tuesday, September 1st. Finally, JPMorgan Chase & Co. reissued a neutral rating on shares of GlaxoSmithKline in a report on Tuesday, September 8th. Four research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. GlaxoSmithKline has an average rating of Hold and a consensus price target of $41.00.

GSK opened at $39.26 on Friday. The firm has a market capitalization of $98.03 billion, a P/E ratio of 12.85, a P/E/G ratio of 2.85 and a beta of 0.65. The firm’s 50 day moving average is $40.05 and its 200-day moving average is $40.26. GlaxoSmithKline has a 52-week low of $31.43 and a 52-week high of $48.25. The company has a quick ratio of 0.69, a current ratio of 0.96 and a debt-to-equity ratio of 1.28.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 29th. The pharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.01). The firm had revenue of $9.46 billion for the quarter, compared to analysts’ expectations of $9.60 billion. GlaxoSmithKline had a net margin of 19.03% and a return on equity of 31.21%. Equities analysts expect that GlaxoSmithKline will post 3.03 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.4914 per share. This represents a $1.97 annualized dividend and a yield of 5.01%. The ex-dividend date of this dividend is Thursday, August 13th. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.47. GlaxoSmithKline’s payout ratio is presently 61.20%.

In related news, Director Plc Glaxosmithkline acquired 361,111 shares of the business’s stock in a transaction on Tuesday, July 21st. The shares were purchased at an average price of $18.00 per share, for a total transaction of $6,499,998.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 10.00% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in GSK. Cpwm LLC grew its holdings in shares of GlaxoSmithKline by 0.8% during the first quarter. Cpwm LLC now owns 31,344 shares of the pharmaceutical company’s stock worth $1,188,000 after purchasing an additional 249 shares during the last quarter. TRUE Private Wealth Advisors grew its holdings in shares of GlaxoSmithKline by 17.8% during the second quarter. TRUE Private Wealth Advisors now owns 1,656 shares of the pharmaceutical company’s stock worth $68,000 after purchasing an additional 250 shares during the last quarter. Capital Investment Advisors LLC grew its holdings in shares of GlaxoSmithKline by 4.5% during the second quarter. Capital Investment Advisors LLC now owns 5,985 shares of the pharmaceutical company’s stock worth $244,000 after purchasing an additional 259 shares during the last quarter. First Command Bank boosted its holdings in GlaxoSmithKline by 38.1% in the second quarter. First Command Bank now owns 975 shares of the pharmaceutical company’s stock valued at $39,000 after acquiring an additional 269 shares during the last quarter. Finally, Keeler Thomas Management LLC boosted its holdings in GlaxoSmithKline by 2.0% in the second quarter. Keeler Thomas Management LLC now owns 13,846 shares of the pharmaceutical company’s stock valued at $564,000 after acquiring an additional 271 shares during the last quarter. 12.12% of the stock is currently owned by institutional investors.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: Profit Margin

The Fly

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.